# Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment

> **NCT01820910** · PHASE2 · COMPLETED · sponsor: **International Extranodal Lymphoma Study Group (IELSG)** · enrollment: 44 (actual)

## Conditions studied

- Marginal Zone Lymphoma of Ocular Adnexal

## Interventions

- **DRUG:** Doxycycline

## Key facts

- **NCT ID:** NCT01820910
- **Lead sponsor:** International Extranodal Lymphoma Study Group (IELSG)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-19
- **Primary completion:** 2016-05
- **Final completion:** 2026-04-01
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01820910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01820910, "Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01820910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*